Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05099666 · ClinicalTrials.gov registry record · Phase 1
Lurbinectedin + Doxorubicin In Leiomyosarcoma
A Phase 1 study of Metastatic Soft Tissue Sarcoma and Advanced Soft Tissue Sarcoma, sponsored by Massachusetts General Hospital.
- Active
- Registry status
- Phase 1
- Development phase
- 62
- Enrollment target
- 6
- Study locations
NCT05099666 is a Phase 1 study of Metastatic Soft Tissue Sarcoma and Advanced Soft Tissue Sarcoma that is active but no longer recruiting, run by Massachusetts General Hospital. The registered enrollment target is 62 participants, below the 135-participant average among 12 other Metastatic Soft Tissue Sarcoma trials with a reported enrollment target (54% lower). The trial reports 6 study locations across 5 states.
The verdict
NCT05099666, a Phase 1 study of Metastatic Soft Tissue Sarcoma and Advanced Soft Tissue Sarcoma, is active but no longer recruiting, sponsored by Massachusetts General Hospital.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 62 participants
- Enrollment target
- 6
- Study locations
Study Summary
This research study involves the study drug lurbinectedin in combination with doxorubicin. This research has two parts. The first part is being done to determine the tolerability of lurbinectedin with doxorubicin in people with soft tissue sarcoma. The second part is a randomized study to determine which is more effective at treating leiomyosarcoma, lurbinectedin with doxorubicin or lurbinectedin alone.
Conditions Studied
Interventions
- DRUG Doxorubicin
- DRUG Lurbinectedin
Study Locations (6)
Massachusetts
- Massachusetts General Hospital - Boston
- Dana Farber Cancer Institute - Boston
Arizona
- Mayo Arizona - Phoenix
Florida
- Mayo Jacksonville - Jacksonville
Minnesota
- Mayo Rochester - Rochester
New York
- Memorial Sloan Kettering - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 62 participants |
| Start Date | 2022-02-04 |
| Est. Completion | 2027-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05099666
The ClinicalTrials.gov registry entry for NCT05099666 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 62 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 135-participant average among 12 other Metastatic Soft Tissue Sarcoma trials with a reported enrollment target (54% lower). The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Metastatic Soft Tissue Sarcoma appearing as the primary indexed condition, and to 2 interventions - of which Doxorubicin is the first listed.
NCT05099666 reports 6 study locations spanning 5 distinct geographic areas - top geographies include Massachusetts, Arizona, Florida.
Frequently Asked Questions
What is clinical trial NCT05099666 about?
NCT05099666 is a clinical study titled "Lurbinectedin + Doxorubicin In Leiomyosarcoma". This research study involves the study drug lurbinectedin in combination with doxorubicin. This research has two parts. The first part is being done to determine the tolerability of lurbinectedin with doxorubicin in people with soft tissue sarcoma. The second part is a randomized study to determine...
What is the current status of trial NCT05099666?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 62 participants. The study started on 2022-02-04. Estimated completion is 2027-07.
What conditions does trial NCT05099666 study?
This clinical trial studies the following conditions: Metastatic Soft Tissue Sarcoma, Advanced Soft Tissue Sarcoma, Advanced Leiomyosarcoma, Leiomyosarcoma Metastatic.
What interventions are being tested in trial NCT05099666?
The interventions under investigation include: Doxorubicin (DRUG), Lurbinectedin (DRUG).
Who is sponsoring clinical trial NCT05099666?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05099666 being conducted?
This trial has 6 study locations across Arizona, Florida, Massachusetts, Minnesota, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Soft Tissue Sarcoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Testing the Addition of an Anti-cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (Gemcitabine) for Soft Tissue Sarcoma
RECRUITING · Phase 1
-
First-in-Human Study of ADCE-D01 in Soft Tissue Sarcoma
RECRUITING · Phase 1
-
Pulmonary Suffusion in Controlling Minimal Residual Disease in Patients With Sarcoma or Colorectal Metastases
RECRUITING · Phase 1
-
SAINT:Trabectedin, Ipilimumab and Nivolumab for Previously Treated Advanced Soft Tissue Sarcoma
RECRUITING · Phase 1
-
Zanzalintinib in Combination With Ipilimumab and Nivolumab in Patients With Metastatic Soft Tissue Sarcoma
RECRUITING · Phase 1
-
T Cell Membrane-Anchored Tumor-Targeted IL12 -Modified TIL Cell Therapy (attIL12-TIL) for Advanced/Metastatic Soft Tissue and Bone Sarcoma Patients.
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.